Small Molecules News and Research

RSS

Safinamide significantly improved motor function in patients with advanced Parkinson's disease

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, and its partner Newron Pharmaceuticals SpA has announced that the first Phase III trial of investigational agent safinamide as adjunctive therapy to levodopa (study 016) met its primary endpoint by increasing daily "ON" time in mid- to late-stage Parkinson's disease patients with motor fluctuations by 1.3 hours.

5 Feb 2009

New chemical keeps stem cells young

Scientists at the Universities of Bath and Leeds have discovered a chemical that stops stem cells from turning into other cell types, allowing researchers to use these cells to develop new medical treatments more easily.

3 Feb 2009

Wyeth and Santaris Pharma to collaborate on RNA-based medicines

Wyeth Pharmaceuticals, a division of Wyeth, and Santaris Pharma have announced that the companies have entered into a worldwide strategic alliance to discover, develop and commercialize new medicines based on Santaris Pharma's proprietary Locked Nucleic Acid (LNA) drug platform, which allows specific targeting and regulation of microRNAs (miRNAs) and messenger RNAs (mRNAs) as a means to affect gene expression mediated by the targeted RNAs.

12 Jan 2009

Discovery of cause of cartilage degeneration in osteoarthritis

The scientists describe their work in this week's Early Edition of the Proceedings of the National Academy of Sciences.

12 Jan 2009

Merck KGaA acquires manufacturing rights for Stimuvax from Oncothyreon

Oncothyreon Inc. announced today that Merck KGaA of Darmstadt, Germany has licensed the right to manufacture Stimuvax and, through its affiliate EMD Serono Canada Inc., purchased current inventory and certain assets utilized for the manufacture of Stimuvax from Oncothyreon for consideration which includes net payments to Oncothyreon totaling approximately U.S. $13 million.

18 Dec 2008

Evolutionary roots of ancient bacteria may open new line of attack on cystic fibrosis

The redox-active pigments responsible for the blue-green stain of the mucus that clogs the lungs of children and adults with cystic fibrosis (CF) are primarily signaling molecules that allow large clusters of the opportunistic infection agent, Pseudomonas aeruginosa, to organize themselves into structured communities.

16 Dec 2008

Both theories about human cellular aging supported by new research

Aging yeast cells accumulate damage over time, but they do so by following a pattern laid down earlier in their life by diet as well as the genes that control metabolism and the dynamics of cell structures such as mitochondria, the power plants of cells.

16 Dec 2008

Researchers map changing epigenetic modifications that enable transposons to run amok

Cold Spring Harbor, N.Y. – Much like cancer cells, plant cells grown for a long time outside of their normal milieu, in culture dishes, have highly unstable genomes.

10 Dec 2008

Researchers identify key step in maturation pathway of telomerase

The Stowers Institute's Baumann Lab has discovered an important step in the maturation pathway of telomerase, the enzyme that replenishes the sequences that are lost at chromosome ends with every cell division.

8 Dec 2008

Motor neurons derived from human embryonic stem cells provide insight into ALS

Two new research studies use motor neurons derived from human embryonic stem (hES) cells to demonstrate that multiple toxic pathways contribute to the devastating degeneration associated with Amyotrophic Lateral Sclerosis (ALS) and that protective therapeutics will need to oppose the disease on multiple fronts.

3 Dec 2008

Anadys Pharmaceuticals receives fast track for ANA598 treatment of chronic hepatitis C virus

Anadys Pharmaceuticals, Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted fast track designation to ANA598 for the treatment of chronic hepatitis C virus (HCV) infection. ANA598 is Anadys' investigational hepatitis C non-nucleoside polymerase inhibitor.

1 Dec 2008

Breakthrough for dialysis patients

Suffering from end-stage renal disease (ESRD), a growing number of patients at the Centre hospitalier de l'Université de Montréal (CHUM), have become the beneficiaries of a North American breakthrough: high efficacy hemodiafiltration (HDF).

28 Nov 2008

MorphoSys and Galapagos enter alliance to co-develop novel therapeutic antibodies in bone and joint disease

MorphoSys AG and Galapagos NV announced today the launch of a long term co-development alliance aimed at discovering and developing antibody therapies based on novel modes of action in bone and joint disease, including rheumatoid arthritis, osteoporosis and osteoarthritis.

26 Nov 2008

New insight into the response of human skin to radiation

Scientists have new insight into the response of human skin to radiation and what drives the most aggressive and deadly form of skin cancer.

20 Nov 2008

Scientists discover new compounds to target muscular dystrophy

Using a drug-discovery technique in which molecules compete against each other for access to the target - the strand of toxic RNA that causes the most common form of muscular dystrophy in adults - a team at the University of Rochester Medical Center has identified several compounds that, in the laboratory, block the unwanted coupling of two molecules that is at the root of the disease.

19 Nov 2008

Researchers find new path to antibiotics in dirt

A teaspoon of dirt contains an estimated 10,000 species of bacteria, but it's only one percent of these microbial bugs - the ones that can be grown easily in a lab - that have brought us antibiotics, anticancer agents and other useful drugs.

7 Nov 2008

Advances in use of stem cells for tissue regeneration

A major issue in the development of regenerative medicine is the cell sources used to rebuild damaged tissues.

7 Nov 2008

Scientists identify compounds for stem-cell production from adult cells

In the study, the scientists screened known drugs and identified small molecules that could replace conventional reprogramming genes, which can have dangerous side effects.

6 Nov 2008

Targeting epigenetic changes helps tackle MLL-AF4 leukemias

A very difficult-to-treat child leukemia may benefit from the discovery of a small but potent epigenetic change that launches the cancer - but could potentially be reversed relatively easily, preventing cancer-promoting genes from being turned on.

4 Nov 2008

YM Biosciences reports on early trials of nimotuzumab in brain metastases and high-grade glioma

YM BioSciences Inc. has announced data from two clinical trials of nimotuzumab, its humanized monoclonal antibody that targets the epidermal growth factor receptor (EGFR). Preliminary results from the two trials which are evaluating nimotuzumab in combination with radiation therapy for the treatment of brain metastases and high-grade gliomas, conducted by YM's licensor, were presented at the 2008 EORTC-NCI-AACR annual meeting recently held in Geneva, Switzerland.

3 Nov 2008